Clinical trial
A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346…
NCT00036413 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00036413 |
|---|---|
| Title | A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis |
| Official title | A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Safety and Dose-ranging Study of Three Oral Doses (0.5 mg, 2.5 mg and 10 mg Once Daily) of TCH346 in Patients With Amyotrophic Lateral Sclerosis. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis |
| Intervention type | Drug |
| Interventions | TCH346 |
| Enrollment | 44 |
| Start date | Jan 1, 2002 |
| Primary completion | Oct 1, 2002 |
| Completion | Oct 1, 2002 |
| First posted | May 10, 2002 |
| Last update posted | Nov 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: